Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. INCPF.US

InnoCare Pharma Limited (INCPF PINK) stock market data APIs

3.26 0(0%) as of February 2, 2024

InnoCare Pharma Limited Financial Data Overview

3.26
3.26
0
3.26
3.26
0 - 0
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

Get InnoCare Pharma Limited Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get InnoCare Pharma Limited End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get InnoCare Pharma Limited latest news via APIs

InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.

BEIJING, July 24, 2024--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in clinical trial of the Company's novel TYK2 (Tyrosine Kinase 2...

InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China

BEIJING, June 20, 2024--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that China National Medical Products Administration (NMPA) has accepted and granted priority review to...
Do you have any questions?
support@eodhistoricaldata.com